Marshall Wace LLP Invests $1.52 Million in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Marshall Wace LLP acquired a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 141,119 shares of the biotechnology company's stock, valued at approximately $1,516,000. Marshall Wace LLP owned 0.17% of Anavex Life Sciences as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in Anavex Life Sciences by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company's stock valued at $242,000 after purchasing an additional 1,191 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Anavex Life Sciences by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company's stock valued at $193,000 after purchasing an additional 1,671 shares in the last quarter. Foster Victor Wealth Advisors LLC lifted its holdings in Anavex Life Sciences by 5.6% during the fourth quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company's stock valued at $405,000 after purchasing an additional 2,000 shares in the last quarter. Opus Capital Group LLC lifted its holdings in Anavex Life Sciences by 6.1% during the fourth quarter. Opus Capital Group LLC now owns 34,700 shares of the biotechnology company's stock valued at $373,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Nwam LLC lifted its holdings in Anavex Life Sciences by 0.3% during the fourth quarter. Nwam LLC now owns 913,051 shares of the biotechnology company's stock valued at $9,806,000 after purchasing an additional 2,575 shares in the last quarter. Institutional investors own 31.55% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on AVXL. HC Wainwright reaffirmed a "buy" rating and set a $42.00 price target on shares of Anavex Life Sciences in a report on Monday, April 7th. D. Boral Capital reiterated a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Anavex Life Sciences Price Performance

Anavex Life Sciences stock opened at $9.58 on Tuesday. The stock has a market cap of $814.91 million, a P/E ratio of -17.42 and a beta of 0.80. Anavex Life Sciences Corp. has a 1 year low of $3.41 and a 1 year high of $14.44. The firm's 50 day moving average price is $8.81 and its 200-day moving average price is $8.82.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. As a group, equities analysts expect that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.